Wuhan YZY Biopharma (2496) has provided additional information regarding the transfer of a land use right and building, originally intended for manufacturing facilities related to the company’s pipeline. The land was acquired in 2012, with plans for commercial production of certain products, including M701. Construction was delayed by external factors such as delayed delivery of the land parcel and COVID-related impacts. Meanwhile, outsourcing to contract manufacturing organizations and the exclusive out-licensing of M701 to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. shifted the company’s need for in-house manufacturing, leading to the transfer decision.

According to the company, the transaction has no impact on existing business strategies, including research and development work on other drug candidates. The maximum consideration was set at RMB36,880,000, while the net proceeds, approximately RMB24,600,000, are planned to support both research and development and general corporate purposes. The company expects these resources to be deployed across clinical and early-stage development activities, as well as working capital needs, during 2026 and 2027, without altering any ongoing operations or commercialization plans.